Dépôt numérique

Redox Based-Peripheral Biomarkers in Alzheimer’s Disease: Challenges, Limits and Prospects

Perrotte, Morgane; Pincemail, Joel; Haddad, Mohamed et Ramassamy, Charles (2016). Redox Based-Peripheral Biomarkers in Alzheimer’s Disease: Challenges, Limits and Prospects In: Inflammation, Aging, and Oxidative Stress. Oxidative Stress in Applied Basic Research and Clinical Practice . Springer International Publishing Switzerland, Switzerland, pp. 377-397.

Ce document n'est pas hébergé sur EspaceINRS.


Alzheimer’s disease (AD) is a progressive neurodegenerative disease with several preclinical and clinical stages. There is growing interest in investigating early biomarkers to adequately define the at-risk state which may ultimately allow preventive strategies and therapeutic agents for the disease- modifying status of AD. The validation of biomarkers for defining the preclinical state of mild cognitive impairment (MCI)/AD is the hope for defining a therapeutic window in which the brain remains responsive to treatment. Biomarkers characterized with neuroimaging and in CSF samples are highly accurate, but they remain difficult to generalize into clinical practice due to the high cost technology associated and the invasive nature. There is still an urgent need to extend these findings to peripheral tissue and fluids. Peripheral, blood or serum–based biomarkers present advantages because they are minimally invasive especially for large scale studies and for repeated measures. However, the search and validation of reliable peripheral biomarkers is a great challenge because blood profile represents an accumulation of the alterations in all tissues. Cumulative studies have reported abnormal levels of antioxidants and oxidative stress in AD and in mild cognitive patients (MCI) in both the brain and the blood stream. There are still several controversial data that require more refine studies, with rigourous and frequent monitoring of these biomarkers during the course of cognitive decline. In this chapter, we will summarize the guideline for different preclinical and clinical stages, the current clinical biomarkers, the state of knowledge of peripheral antioxidant- and oxidized macromolecules-based biomarkers, the challenges for the identification and validation of oxidative peripheral biomarkers, the role and criteria of the reference group, the importance of the pre-analytical procedure and the standardisation of methods.

Type de document: Chapitre de livre
Mots-clés libres: Mild cognitive impairment; CSF; ß-amyloid; Tau; ADNI; Antioxidants; Lipid peroxidation; Protein carbonylation
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 13 mars 2019 14:56
Dernière modification: 19 oct. 2023 13:12
URI: https://espace.inrs.ca/id/eprint/5877

Gestion Actions (Identification requise)

Modifier la notice Modifier la notice